# Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

> **NCT00540592** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2007 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
- **BIOLOGICAL:** Fluarix

## Key facts

- **NCT ID:** NCT00540592
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-08
- **Primary completion:** 2008-06-10
- **Final completion:** 2008-06-10
- **Target enrollment:** 2007 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540592, "Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00540592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*